Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™
Nov 29th 2009
ATIR™ for reduction of transplant related mortality following an allogeneic stem cell transplantation using a mismatched donor...
read more 
(NL version)
(NL version)
Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting
Nov 5th 2009
Biopharmaceutical company Kiadis Pharma announces the presentation of results obtained in two clinical trials with its lead product ATIR™. Dr. Denis...
read more (NL version)
(NL version)
- Kiadis Pharma appoints Stefaan Allemeersch as Vice President Business Development - Jun 18th 2009 (NL)
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium - Apr 8th 2009 (NL)
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting - Feb 6th 2009 (NL)
- Kiadis Pharma appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer - Jan 6th 2009 (NL)
- Kiadis Pharma announces appointment of Mark Skaletsky to its Supervisory Board - Dec 11th 2008 (NL)
1096 EG Amsterdam
The Netherlands
t +31 (0)20 314 02 50
f +31 (0)20 314 02 51